Clinical trial
A Pilot Study of Rituximab-Gemcitabine-Navelbine for Relapsed/Refractory Hodgkin's Lymphoma
NCT00881387 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Study of Rituximab-Gemcitabine-Navelbine for Relapsed/Refractory Hodgkin's Lymphoma
- Lead sponsor
- University of Miami
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- February 28, 2009
- Completion date
- October 31, 2012
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.